Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever: A Double-blind, Randomized Control Trial

NCT06744777 is registered in ClinicalTrials.gov with Khyber Medical University Peshawar as lead sponsor.

NCT NCT06744777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06744777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever: A Double-blind, Randomized Control Trial
Lead sponsor
Khyber Medical University Peshawar
Phase
Phase 3
Overall status
Completed
Start date
December 17, 2024
Completion date
May 29, 2025
Enrollment
284 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

dengue fever, dengue hemorrhagic fever, severe dengue